We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Antineoplastic Effect of Heparin on Colorectal Cancer: A Review of the Literature.
- Authors
Giannas, Emmanuel; Kontovounisios, Christos
- Abstract
Heparin and derivatives are commonly used for thrombophylaxis in surgical colorectal cancer (CRC) patients. Recent studies have suggested that, besides its protective effect on the incidence of venous thromboembolism, heparin has an anti-cancer effect. The aim of this review was to explore the literature and report the antineoplastic effect of heparin and derivatives on CRC. MEDLINE and EMBASE databases were searched for relevant articles. Nineteen studies were included (n = 19). Fifteen were lab studies conducted in vivo or in vitro on CRC cell lines and/or mice (n = 15). Four were in vivo clinical studies (n = 4). CRC tumor growth was reduced by 78% in one study, (p < 0.01), while tumorigenesis was suppressed in heparin-treated mice in seven studies. A high dose of low molecular weight heparin for extended duration significantly reduced post-operative VEGF, suggesting that such a regime may inhibit tumor angiogenesis and distant metastasis. A randomized trial demonstrated the antineoplastic effect of nadroparin as the 6 month survival in palliative patients increased. Another study has reported that disease-free survival of CRC patients was not affected by a similar tinzaparin regime. The anti-cancer properties of heparin and derivatives are promising, especially in lab studies. Further clinical trials are needed to investigate the anti-cancer benefit of heparin on CRC.
- Subjects
LITERATURE reviews; LOW-molecular-weight heparin; COLORECTAL cancer; HEPARIN; ANTINEOPLASTIC agents; LYMPHATIC metastasis
- Publication
Journal of Clinical Medicine, 2023, Vol 12, Issue 22, p7173
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm12227173